ICU Medical (NASDAQ:ICUI) Raised to “Buy” at Wall Street Zen

ICU Medical (NASDAQ:ICUI) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Friday.

ICUI has been the subject of several other research reports. Piper Sandler began coverage on ICU Medical in a research note on Friday, August 15th. They issued an “overweight” rating and a $145.00 target price for the company. Raymond James Financial dropped their price objective on ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating for the company in a research note on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $179.00.

ICU Medical Stock Up 4.5%

Shares of ICUI opened at $131.24 on Friday. The firm has a market cap of $3.24 billion, a P/E ratio of -86.34 and a beta of 0.86. The stock has a 50 day simple moving average of $126.51 and a two-hundred day simple moving average of $134.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.44 and a quick ratio of 1.17. ICU Medical has a 1 year low of $107.00 and a 1 year high of $196.26.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.44 by $0.66. The business had revenue of $543.57 million during the quarter, compared to analyst estimates of $543.33 million. ICU Medical had a positive return on equity of 7.24% and a negative net margin of 1.56%.ICU Medical’s revenue for the quarter was down 8.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.56 earnings per share. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. On average, analysts forecast that ICU Medical will post 4.11 earnings per share for the current fiscal year.

Insider Buying and Selling

In other ICU Medical news, Director David C. Greenberg bought 1,200 shares of the firm’s stock in a transaction that occurred on Wednesday, August 27th. The stock was bought at an average price of $126.42 per share, for a total transaction of $151,704.00. Following the completion of the acquisition, the director directly owned 7,960 shares in the company, valued at $1,006,303.20. The trade was a 17.75% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Vivek Jain bought 21,929 shares of the firm’s stock in a transaction that occurred on Thursday, August 14th. The shares were acquired at an average price of $112.84 per share, with a total value of $2,474,468.36. Following the acquisition, the chief executive officer owned 130,149 shares of the company’s stock, valued at $14,686,013.16. This represents a 20.26% increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On ICU Medical

Hedge funds and other institutional investors have recently made changes to their positions in the business. Cullen Frost Bankers Inc. bought a new position in shares of ICU Medical during the second quarter valued at approximately $38,000. GAMMA Investing LLC raised its holdings in ICU Medical by 27.2% in the first quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier’s stock worth $99,000 after purchasing an additional 153 shares in the last quarter. Blue Trust Inc. raised its holdings in ICU Medical by 23.0% in the first quarter. Blue Trust Inc. now owns 801 shares of the medical instruments supplier’s stock worth $111,000 after purchasing an additional 150 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in ICU Medical by 11.6% in the second quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock worth $128,000 after purchasing an additional 101 shares in the last quarter. Finally, Headlands Technologies LLC bought a new position in ICU Medical in the second quarter worth $177,000. Institutional investors own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.